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ABSTRACT
Bone metastases represent an important complication of malignant tumours. 
Despite improvement in surgical techniques and advances in systemic therapies, 
management of patients with bone metastatic disease remains a powerful cornerstone 
for the radiation oncologist. The primary goal of radiation therapy is to provide pain 
relief, preserving patient’s quality of life.
INTRODUCTION
Solid tumors frequently metastasize to bone. 
The exact incidence of bone metastases is difficult to 
extrapolate, but it has been estimated that approximately 
35.000 people per year in Italy will develop bone 
metastases [1]. Depending on primary tumor site, the 
incidence of bone metastases varies extensively, with 
breast, prostate or lung cancer accounting for over 85% of 
patients with metastatic disease. Bone metastases usually 
appear after adequate therapy for primary tumor, but in 
up to 20% of cases they are the presenting symptom at 
diagnosis. 
Bone metastasis are usually associated with a poor 
prognosis with median survival rates limited to several 
months. However, year after year, significant progress in 
systemic and supportive therapies have increased patients’ 
life expectancy. Therefore, patients with metastatic 
disease represent a heterogeneous patient group and 
overall survival depend on both primary tumor site and 
concomitant presence/absence of visceral metastases. 
Nowadays, patients who develop oligometastases from 
prostate and breast cancer have a longer median survival 
compared to those with bone-only metastatic lung cancer 
(36 months versus 6 months) [2-3]. 
Independently of clinical outcomes, the vast 
majority of patients with bone metastases requires an 
active treatment, due to pain, difficulty with ambulation, 
pathologic fractures, spinal cord compression, 
hypercalcemia and neurologic deficits. 
Skeletal metastases are the most common 
localization, occurring principally in lumbar and thoracic 
spine, pelvis, ribs and long bones of the upper and lower 
extremity. Certain skeletal sites are pathognomonic of 
specific primary tumor. For instance, involvement of the 
scapular is more common with renal primaries, whereas 
skull metastases develop more frequently from primary 
breast cancer. 
Several variables, including life expectancy, 
predicted outcomes, disease characteristics and patient 
preferences must be considered to tailor the best cancer 
therapy for the individual patient. Radiation therapy 
(RT) can represent an effective palliative intervention 
in metastatic disease to maintain and improve patient’s 
quality of life (QoL). The majority of patients will 
experience pain during their disease course and pain 
management can significantly improve their QoL. This 
review provides highlights in effects, clinical efficacy and 
tolerability of RT delivered by linear accelerators in the 
management of patients with bone metastases. 
INDICATIONS AND AIMS OF RADIATION 
THERAPY
The important role of RT in the palliation of bone 
metastases is well recognized. RT is performed primarily 
to relieve pain, definitely control a bone affected from 
metastases and prevent pathologic fractures as well 
as spinal cord compression. Radioisotopes can be 
administered for more diffuse bone pain that is not 
eligible for palliative RT, whereas bisphosphonates are 
usually considered in case of multiple unpainful skeletal 
metastases. 
The goals of RT are to improve QoL, reduce 
Review
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analgesic requirements and maintain or ameliorate skeletal 
function. Beneficial effects on pain may necessitate several 
days to a few weeks, so analgesic medication must be 
optimized during that interval [4]. 
The initial patient evaluation should be adequate and 
accurate, using validated instruments specific for cancer 
patients in palliative care. It is important to report patient 
symptom experience, using a pain scale of 0 - 10, in which 
0 represents no pain and 10 represents maximum pain [5]. 
The European Organisation for Research and Treatment 
of Cancer Quality-of-Life Questionnaire (EORTC 
QLQ)-C30, as well as his short form EORTC QLQ-C15-
PAL, is commonly used to assess QoL in this setting of 
patients [5-6 ].
Briefly, first-line palliative RT is indicated for 
symptomatic bone metastases, after the appearance of new 
painful site or after failure or insufficient effect subsequent 
to a first irradiation.
EFFECTS OF RADIATION THERAPY ON 
BONE METASTASES
Due to the persistence of red bone marrow, the 
axial skeleton is seeded more than the appendicular 
skeleton. Bone metastases are mainly associated to an 
overstimulation of osteoclasts or osteoblasts causing 
a lytic or blastic lesion, respectively. Both lytic and 
blastic lesions can cause bone pain. Osteoclast activation 
contributes to painful osteolytic metastases due to higher 
rate of pathologic fractures. Bone cancer pain principally 
depends on three mechanisms [4, 7]. Firstly, tumor cells 
alter the physiological equilibrium between osteoclasts 
and osteoblasts, determining structural degradation of 
the bone. Secondly tumor cells may directly invade nerve 
root or may increase expression of chemical mediators 
which stimulate nerve fibers. Lastly, surrounding muscles 
may spasm, in order to maintain skeleton stability. These 
conditions can cause discomfort. The beneficial effects 
of RT on bone pain are mainly related to its capability 
to produce ossification. Moreover ionizing radiation are 
able to diminish osteoclasts activation and kill tumor cells 
[7]. There will therefore be a reduction in tumor volume, 
preserving discomfort to adjacent nerves. Furthermore, the 
reported evidence of symptom relief within 24 hours after 
initial RT suggests that reduction of both inflammatory 
cells and chemical pain mediators is involved in this rapid 
reaction [8]. 
FRACTIONATION SCHEDULES
The optimal fractionation schedule is still an 
unresolved issue. In clinical practice, the selection 
of the fractionation schemes is often influenced by 
patient characteristics (performance status, compliance 
to treatment, life expectancy), tumor-related factors 
(histology of the primary tumor, interval time from 
primary diagnosis to bone metastases, time of developing 
pain or neurologic deficits before RT) and logistic issues 
(treatment duration time, validity of family members 
assistance, hospital location, cost of therapy). A summary 
of the main clinical circumstances is provided in Table 1. 
Painful uncomplicated bone metastases
Single fraction RT schedule, prescribed to the 
appropriate target volume, is recommended as the 
standard of care for the treatment of symptomatic and 
uncomplicated bone metastases [9].
*clinical trials
Abbreviations: 3D-CRT: three-dimensional conformal radiation therapy; SBRT: stereotactic body radiation
Table 1: Bone metastases radiotherapy suggestions
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During the past two decades, multiple randomized 
controlled trials (RCTs) have demonstrated pain relief 
equivalency between a single 8 Gray (Gy) fraction 
and multiple fraction regimens, including 30 Gy in 10 
fractions, 24 Gy in 6 fractions and 20 Gy in 5 fractions 
[10-15]. Recently, based on 25 RCTs, a meta-analysis 
has been performed to provide substantial evidence for 
defining the optimal RT fractionation schedule [16]. 
Retreatment rates to the same anatomic site due to 
recurrent pain were higher in those who received single 
fractions compared to fractionated treatment courses 
(20% versus 8%, p < 0.00001). Single fraction treatment 
optimized patient and caregiver convenience and was 
related with lower acute toxicity, including nausea and 
vomiting, fatigue, diarrhoea and skin reactions. Single 
fraction was also associated with a higher pathological 
fracture and spinal cord compression rates compared 
to multiple fraction treatment, but this result did not 
reach statistical significance (odds ratio [OR] 1.10, 95% 
confidence interval [CI] 0.65 - 1.86, p = 0.72 and OR 1.44, 
95% CI 0.90 - 2.30, p = 0.13, respectively). However, the 
limitation of this analysis is mostly related to the primary 
end-points heterogeneity of the RCTs included. 
Despite its proven clinical effectiveness and its 
cost efficiency, worldwide the single fraction regimen is 
underused into daily practice for palliative RT for painful 
bone metastases [17]. The reasons proposed for this 
reticence are mainly related to a lack of experience with 
large fraction sizes, participation in RCTs and influence 
of reimbursement [17]. Since target volume as well as 
patient characteristics and tumor-related factors were not 
specifically addressed in RCTs, literature evidence does 
not support the choice of RT regimen based on these 
considerations [9]. 
In case of spinal metastases, percutaneous 
vertebroplasty combined with adjuvant RT seems to be 
better that RT alone to relief pain, maintain vertebral body 
stability and improve patients’ QoL [18].
Pathologic fractures
Although data are limited, a multiple fractionated 
treatment, including 20 Gy in 5 fractions and 30 Gy in 10 
fractions, could be considered appropriate in those patients 
at risk of pathologic fractures, in order to guarantee 
a tumor down-staging prior to surgical approach. 
On the other hand, where the treatment objective is 
tumor shrinkage and pain control in presence of a bone 
lesion associated with large soft tissue mass, no dose-
fractionation recommendation can be define [9]. 
Spinal cord compression
Metastatic spinal cord compression represents a 
medical emergency. An immediate, aggressive treatment 
approach is essential to preserve neurologic function 
and to improve patient’s QoL. RT, surgery or combined 
modality constitutes the management for spinal cord 
compression. Although, in the past, RT was considered 
the standard of care, nowadays, due to improvements in 
neurosurgical techniques, new evidence suggested that 
direct decompressive surgery plus postoperative RT seems 
to be superior to RT alone for spinal cord compression 
caused by metastatic tumor [19]. The typical dose is 20 
Gy (4 Gy/fraction) or 30 Gy (3 Gy/fraction). In those 
patients unfit for surgery, RT alone is the recommended 
treatment, although the optimal dose and fractionation 
schedule is not still established. Considering the limited 
expected survival in most spinal cord compression patients 
and that the majority of the patients are quite debilitated, 
a shorter treatment program is highly desirable. Rades 
et al [20] presented the largest spinal cord compression 
patient cohort comparing five different RT schedules to 
investigate the optimal therapy for these patients. Five 
RT schedules were compared: 8 Gy (sigle fraction), 20 
Gy (4 Gy/fraction), 30 Gy (3 Gy/fraction), 37.5 Gy (2.5 
Gy/fraction) and 40 Gy (2 Gy/fraction). No significant 
differences in term of improvement of motor function 
after RT and acute or late toxicity were found between the 
five groups. Recurrences occurred more frequently after 
shorter treatment course than protracted schedules; but 
patients irradiated with shorter regimens were retreated, 
although patients submitted to protracted schedules 
received no further treatment at the time of recurrence. In 
a randomized trial, Maranzano et al [21] have compared 
different dose fractionation schedule, in patients with 
spinal cord compression and life expectancy < 6 months. 
Patients were randomized to single 8 Gy fraction versus 
multiple fractions. Both regimens were effective with 
no significant difference in back pain relief (56% versus 
59%), motor capacity (68% versus 71%) and good 
bladder function (90% versus 89%). Authors suggested 
single fraction RT has been recommended as regimen of 
choice in clinical practice for patients with spinal cord 
compression and short expected survival [22]. 
RESPONSE TO RADIATION THERAPY
Response categories
In order to reduce the variation in the measurement 
of pain - self-reporting pain versus radiation oncologist-
based - among trials, the International Bone Metastases 
Consensus Working Party on palliative radiotherapy 
defines and recommends the following response categories 
[5]: 1) Complete response: a pain score of 0 at treated 
site with no concomitant increase in analgesic intake 
(stable or reducing analgesics in daily oral morphine 
equivalent [OMED]). 2) Partial response: pain reduction 
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of 2 or more at the treated site on a scale of 0 to 10 scale 
without analgesic increase, or analgesic reduction of 
25% or more from baseline without an increase in pain. 
3) Pain progression: increase in pain score of 2 or more 
above baseline at the treated site with stable OMED, or 
an increase of 25% or more in OMED compared with 
baseline with the pain score stable or 1 point above 
baseline. 4) Intermediate response: any response that is 
not captured by the complete response, partial response, 
or pain progression definitions.
Response to treatment
Considering that single fraction RT is equally 
effective to multiple fractions for most patients, the overall 
response percentages is presented. There is no consistent 
dose-response relationship for pain relief, suggesting that 
response is mainly mediated by a change in the local bone 
environment [8]. Globally, the rates of pain relief ranges 
from 50% to 85%, with up to one-third reporting complete 
response [23]. Patients receiving RT for bone metastases 
will experience complete to partial pain relief, typically 
within 4 weeks after RT. Mean duration of remission is 
approximately 19 weeks. Patients with breast cancer or 
prostate cancer have higher response rates, as well as 
duration of remission, than patients with lung cancer or 
other primary tumors [24].
TOXICITY OF RADIATION THERAPY
QoL plays a progressively more important role 
in the evaluation of overall treatment efficacy. Due to 
short life expectancy of the vast majority of metastatic 
patients, acute toxicity is much more clinically relevant 
than late complications. However, with improvement in 
systemic therapies, some patients, especially those with 
oligometastases, have a better prognosis and, thus, are 
potentially at risk of developing late toxicity.
Toxicity depends mostly on the total dose delivered 
to the normal tissues adjacent to the target volume. It 
is predictable and generally self-limiting. No major 
differences in gastrointestinal disturbances (including 
nausea, vomiting and diarrhea), itching, skin reactions and 
tiredness were reported between single fraction or multiple 
fractions regimens [16].
Side effects are manageable with conservative 
measures. For instance, for treatment over the abdomen or 
with large target volumes in the pelvis, it is reasonable to 
use a prophylactic antiemetic to reduce acute nausea and 
vomiting. 
Pain flare is described as a temporary increase in 
Figure 1: Isodose distribution for three-dimensional conformal radiation therapy (3D-CRT) to dorsal vertebra.
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bone pain at the treated metastatic site, during or shortly 
after RT completion [25]. Its physiopathology is still 
unknown. It has been suggested
to arise from the release of biochemical mediators of 
inflammation or the edema compressing nerves in the area 
of treatment [26]. Pain flare incidence has been reported 
only in recent studies, with great variability from 2% to 
40% [27-28]. Patients receiving a single 8 Gy fraction are 
at higher risk of pain flare, whereas patients with steroids 
prescribed as part of their systemic therapy are less 
likely to experience it [29]. The use of anti-inflammatory 
medications can prevent or minimize the risk of pain flare. 
RADIATION THERAPY TECHNIQUES
Three-dimensional conformal radiation therapy
Three-dimensional conformal radiation therapy (3-
DCRT) is now firmly considered the standard of practice 
to treat bone metastases. 3-DCRT allows to conform dose 
distribution to the target volume, reducing dose to the 
surrounding normal tissues. Before treatment, a computed 
tomography (CT) scan of the affected anatomic site is 
obtained. Patient should be positioned in a comfortable 
and reproducible position. Using a three-dimensional CT 
planning, the most conformal treatment plan is prepared. 
The goal is to deliver the maximum dose to the target 
volume and spare the normal tissues. Figure 1 illustrates 
treatment of a spinal metastases with single 8 Gy fraction. 
In vertebral metastases, radiation fields should include the 
involved vertebral body (and if necessary the soft tissue 
tumor), plus a vertebral body below and above.
Stereotactic body radiation
Stereotactic body radiation (SBRT) is a modern 
treatment modality that delivers high doses to metastatic 
bone with a great accuracy, minimizing the dose to the 
adjacent critical structures, primarily spinal cord and 
cauda equine, but also lung, esophagus, kidney, bowel and 
contiguous vertebral bodies. Considering the heterogeneity 
of prognosis for patients with bone metastases, there is 
a consistent interest to identify a subset of patients with 
oligometastatic disease - up to three metastatic lesions - 
who may achieve more durable pain control with SBRT 
[22, 30].
SBRT is performed on vertebral body lesions, 
without extension to the posterior cortical, allowing for 
distance between target volume and spinal cord and thus 
limiting neural structures to threshold below the dose 
of radiculopathy and myelopathy. SBRT treatment field 
encompass only the tumor lesion. This equates to the 
anterior portion of the involved vertebral body, with the 
Figure 2: Target volume and organs at risk definition in a stereotactic body radiation therapy (SBRT).
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inclusion of posterior wall and pedicles in more posterior 
bone metastases site. A typical target volume definition is 
shown in Figure 2.
Indications for SBRT include solitary or up to three 
vertebral metastases. Lesions should be smaller than 5 
cm in diameter. Symptomatic spinal cord compression 
can represent a contraindication to SBRT treatment [31]. 
Effective patient immobilization, as well as meticulous 
quality control, are essential during treatment. There 
is no consensus on dose and fractionation for SBRT. 
Several fractionation schedules have been proposed from 
single 15-24 Gy fraction to multiple fractions schedules 
delivering a total dose of 18-36 Gy. Efficacy and safety 
data for SBRT are mostly from retrospective single-
institution analysis. Generally pain relief and local tumor 
control were recorded in over 80% of metastatic patients, 
with an extremely low (less than 0.5%) incidence of 
myelopathy [32]. 
RE-IRRADIATION
Re-irradiation to the same bone site should be 
considered after initial palliative RT in the following 
scenario: 1) no response in previously irradiated area; 2) 
partial response and the hope of additional benefit from 
repeat treatment; 3) pain relapse after initial satisfactory 
response. 
Patients requiring re-irradiation represent a 
substantial group, considering that up to 40% of patients 
do not obtain any pain relief after initial RT and pain 
relapse occurs in approximately 50% of initial responders 
within one year after RT [33]. Globally, time to response 
after re-irradiation varies from 3 to 5 weeks [33]. Patients 
initially treated with single fraction of 8 Gy are 2.6 
times more likely to require re-treatment than those who 
received multiple fractions [16]. Interestingly, radiation 
oncologists seem more likely to offer re-treatment after 
initial 8 Gy RT versus initial multiple fractions schedule, 
may be due to the limits of radiation tolerance [24, 34]. 
Most multiple fractions patients were not referred to re-
treatment due to misconception of high myelopathy risk.
Despite the huge number of patients undergoing re-
irradiation, the paucity of data limits definitive guidelines. 
The International Bone Metastases Consensus Working 
Party published a consensus on palliative RT in an attempt 
to promote appropriate set of end-points, including re-
irradiation criteria [35]. In the updated version, the 
Consesus Working Party recommends a 4-week interval 
for re-treatment in those patients who do not achieve a 
response to initial RT [5]. The best available evidence 
on re-treated patients was presented by van der Linden 
et al [24]. They reanalyzed the database of the Dutch 
Bone Metastasis Study, the largest study on the effect on 
painful bone metastases of 8 Gy single fraction versus 24 
Gy in multiple fractions. The choice to re-irradiate was 
left to the radiation oncologist’s discretion. Mean time to 
re-treatment was 13 weeks in single fraction patients and 
21 weeks in multiple fractions patients. For the different 
primary tumors, mean time to re-treatment was 22 weeks 
for prostate cancer, 14 weeks for breast cancer, 11 weeks 
for lung cancer and 13 weeks for other primary tumors. 
Apparently, a longer waiting period to start re-irradiation 
was observed in patients with prostate cancer compared 
with the other primary tumors. However only 19% of 
progressive prostate patients responded again. Thus it 
seems appropriate to no postpone re-irradiation for too 
long. Regarding the effectiveness of re-treatment, response 
was recorded in 66% initial 8 Gy patients and 46% initial 
multi fractions patients (p = 0.12), with longer mean 
duration of remission in initial single fraction patients (16 
weeks versus 8 weeks). 
At present no definitive recommendation can be 
given regarding dose and fractions in re-irradiation. 
Single 8 Gy treatment should be considered a valid 
option. This suggestion is based on the results of the RCT 
that compared the pain-relieving efficacy of two dose 
fractionation schedules - single 8 Gy fraction versus 20 
Gy in multiple fractions - in patients with bone metastases 
requiring re-treatment [36]. This was a multicentre, non-
inferiority trial and a total of 850 patients were randomly 
assigned to single or multiple fractions re-irradiation. In 
term of response and efficacy, 8 Gy in a single fraction 
was non-inferior to 20 Gy administered in multiple 
fractions. Globally, RT with 8 Gy was less toxic than 20 
Gy treatment, whereas QoL, assessed using the EORTC 
QLQ-C30, was similar between the two treatment 
regimens. 
In case of localized RT-refractory painful bone 
metastases, SBRT could be considered a treatment option. 
In previously irradiated bone metastases, several phase I/II 
trials tested different doses, including 24 Gy in 3 fractions 
and 10-30 Gy in 1-5 fractions [37-38]. However, specifics 
of dosing and target volume delineation are still not well-
defined and there is no evidence of superiority of SBRT 
over conventional EBRT with respect to pain control. 
SBRT should be reserved for patients who are treated in 
specialized centers and preferably within the confines of 
a therapeutic clinical trial [23]. Careful patient selection 
in terms of performance status, number of metastases, 
primary tumor type, and loco-regional anatomy, is 
paramount. 
FUTURE PERSPECTIVES
Currently, new emergent targeted therapies blocking 
key agents for the development and progression of bone 
metastases have been tested, especially in prostate cancer 
field [39]. Based on the available literature, several new 
bone target therapies, including mTOR inhibitors, anti-
androgens and radium-223 have shown to improve overall 
survival in bone metastatic patients, whereas other new 
molecules, such as anti RANKL/RANK pathway are still 
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under investigation [39]. Targeted therapies represents an 
attractive therapy that should be added to bone metastatic 
clinical trial practice but how best to incorporate it with RT 
remains an urgent need. Data regarding the safety profile 
of combining RT and targeted therapies in bone metastatic 
patients are very limited and further investigations are 
needed [40]. 
Recently, the combination of RT and ablative 
approaches, including radiofrequency ablation (RFA), 
high intensity focused ultrasound (HIFU) and cryoablation 
has been proposed as therapeutic option to control painful 
bone metastases [41-42]. But it is too early to establish 
definitive conclusions. The sequence of treatments, as 
well as the optimal combinations should have a better 
understanding. 
SUMMARY
RT is a well-accepted local treatment modality for 
patients with painful bone metastases. Effective use of RT 
requires a well consolidate multidisciplinary approach and 
a close cooperation between surgical, radiation and clinical 
oncology, as well as nursing personal is paramount. 
Single fraction treatment is efficacious and cost-
effective for the relief of painful bone metastases.
Additional data are required to define the correct 
fractionation in spinal cord compression and pathological 
fractures. SBRT has emerged as a modern high precision 
technique able to improve pain control with durable 
effect, especially in retreatment setting or oligometastatic 
patients. However, further data are paramount to better 
define its role in this scenario.
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